Document Detail

TERIMA-2: national extension of thrombolytic treatment with recombinant streptokinase in acute myocardial infarct in Cuba.
MedLine Citation:
PMID:  11330244     Owner:  NLM     Status:  MEDLINE    
AIM: The extension of recombinant streptokinase (rSK) use in Cuba and to evaluate its effect on in-hospital mortality of patients with acute myocardial infarct (AMI). METHODS: A phase IV clinical study was performed in 52 hospitals from the 14 Cuban provinces. Patients (any age) with ST segment elevation or bundle branch block were included if they came less than 12 h after the onset of AMI symptoms, without contraindications for thrombolytic therapy. They received 1.5 x 10(6) IU of rSK (Heberkinasa, Heberbiotec, Havana) intravenously, during one hour. Endpoints were death due to cardiac (pump failure, wall rupture, arrhythmia) or any cause and cardiovascular events at hospital release. RESULTS: The study included 2,923 patients, 22-98 years-old, 74.4% men, which represented 37.2% of the total AMI patients attended at the participating hospitals from November 1992 to May 1995. Aspirin was given to 92.5% and betablockers to 65.3%. AMI was confirmed in 93.5% of the patients. The mean symptoms--rSK infusion time interval was 5.25 h (22.3% of the patients treated within the first 3 h). 302 patients died, 80.1% of them due to cardiac causes, 12 attributed to rSK treatment, and 16 to non-cardiac causes. This 10.4% mortality represents a 4% absolute and a 28.3% relative reduction (179 lives saved per year) as compared to a survey made before rSK treatment was introduced. In a logistic regression analysis, mortality was favored by age, symptoms--infusion time. Killip class, and not having taken aspirin or betablockers. Feminine gender was close to the limit of significance. The more frequent adverse events were arrhythmias and hypotension during infusion. Major bleeding occurred in 27 patients (9 strokes). CONCLUSION: Local recombinant-DNA biotechnology can influence on a major health problem with favorable cost/ and risk/benefit balances, not possible in a developing country with an imported drug. The further extension of this treatment in the country is feasible and recommended, monitored through an appropriate pharmacosurveillance program.
Related Documents :
12735564 - Preliminary experience with the lionheart left ventricular assist device in patients wi...
23129544 - Energy titration strategies with the endoscopic ablation system: lessons from the high-...
2708444 - Long-term clinical outcome of patients with tricuspid atresia. i. "natural history".
2279574 - The role of central haemodynamic monitoring in abdominal aortic surgery. a prospective ...
22773364 - Has "respiratory coaching" before deep inspiration an impact on the incidence of transi...
6400534 - Treatment of skin and soft-tissue infections with cefsulodin.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  84     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-01-10     Completed Date:  2001-05-31     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  949-54     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cuba / epidemiology
Middle Aged
Myocardial Infarction / complications,  drug therapy*,  mortality
Recombinant Proteins / administration & dosage,  adverse effects,  standards
Regression Analysis
Risk Factors
Streptokinase / administration & dosage*,  adverse effects,  standards
Thrombolytic Therapy / mortality,  standards*
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No Article Title
Next Document:  A comparison of outcomes in osteoarthritis patients undergoing total hip and knee replacement surger...